GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enzychem Lifesciences Corp (XKRX:183490) » Definitions » Debt-to-EBITDA

Enzychem Lifesciences (XKRX:183490) Debt-to-EBITDA : -9.40 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Enzychem Lifesciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Enzychem Lifesciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩3,545 Mil. Enzychem Lifesciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩1,534 Mil. Enzychem Lifesciences's annualized EBITDA for the quarter that ended in Mar. 2024 was ₩-540 Mil. Enzychem Lifesciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -9.40.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Enzychem Lifesciences's Debt-to-EBITDA or its related term are showing as below:

XKRX:183490' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.91   Med: -1.08   Max: -0.21
Current: -1.07

During the past 10 years, the highest Debt-to-EBITDA Ratio of Enzychem Lifesciences was -0.21. The lowest was -2.91. And the median was -1.08.

XKRX:183490's Debt-to-EBITDA is ranked worse than
100% of 661 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs XKRX:183490: -1.07

Enzychem Lifesciences Debt-to-EBITDA Historical Data

The historical data trend for Enzychem Lifesciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzychem Lifesciences Debt-to-EBITDA Chart

Enzychem Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.21 -2.73 -2.91 -2.87 -0.98

Enzychem Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.11 -1.04 -0.86 -1.04 -9.40

Competitive Comparison of Enzychem Lifesciences's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Enzychem Lifesciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzychem Lifesciences's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enzychem Lifesciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Enzychem Lifesciences's Debt-to-EBITDA falls into.



Enzychem Lifesciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Enzychem Lifesciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4047.506 + 1609.453) / -5746.839
=-0.98

Enzychem Lifesciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3544.939 + 1534.101) / -540.38
=-9.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Enzychem Lifesciences  (XKRX:183490) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Enzychem Lifesciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Enzychem Lifesciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzychem Lifesciences (XKRX:183490) Business Description

Traded in Other Exchanges
N/A
Address
27 Gangnamdae-ro Seocho-gu, 10th Floor, aT Center, Seoul, KOR, 135-280
Enzychem Lifesciences Corp develops and produces APIs and functional health foods. It manufactures veterinary medicine tablets, capsules, syrups, injections, ointments, solutions for the diagnosis and prevention of various diseases. The company is also developing drugs to treat chemotherapy-induced neutropenia, chemo-radiation therapy-induced oral mucositis, asthma, psoriasis, rheumatoid arthritis, and others.

Enzychem Lifesciences (XKRX:183490) Headlines

No Headlines